Core--Thrombosis

核心——血栓

• 批准号: 6866589
• 负责人: Juan Jose Badimon
• 金额: $ 10.27万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-01 至 2006-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6866589
• 关键词: biomedical facility; blood chemistry; blood coagulation; human tissue; thromboplastin; thrombosis

DESCRIPTION (Applicant's Abstract) Aims: The overall objective of the Core is to offer the biochemical and thrombosis support to all the individual projects of the SCOR. This Core will be responsible for the performance and evaluation of the studies involving blood thrombogenicity with Badimon perfusion chamber and all the different hematological and biochemical parameters required for the development of the different projects included in the present SCOR application. The Clinical Project (Dr. V. Fuster) includes approximately 500 perfusion studies. The cohorts of diabetic (n=50) and hyperlipidemic (n=50) patients will be studied at baseline and 3-, 9- and 18- months after treatment initiation; the smokers will be studied at baseline and 4-weeks after smoking cessation). These patients will be monitored for plasma levels of TFPI, TF antigen and activity, C-Reactive Protein at baseline, 3, 9 and 18-months after treatment initiation. In addition, the Core will also be responsible for the determination of TIPI and TF antigen and activity in the samples obtained through our collaboration with the investigators of the REVERSAL and WOMEN'S HEALTH STUDY (See Dr. Fuster's Project). The core will be responsible for the determination and management of the biochemical data of the hyperlipidemic, and diabetic and smokers involved in the Clinical Project (D. V. Fuster). The Core will also be responsible for all the blood thrombogenicity studies described in Dr. Taubman's and Nemerson's project as well as the determination of plasma levels of TF antigen and activity, TIPI, C-Reactive Protein and Troponin-I in the experimental studies of this project. The Core will also monitor the levels of anticoagulation (aPTT, PTT, TT) and the blood cell count (by using a cell counter equipped with veterinarian software) of the animals from Taubman's project and cholesterol levels from Dr. Harpel's project.

目的：核心的总体目标是为SCOR的所有单个项目提供生物化学和血栓形成支持。该核心将负责执行和评价涉及Badimon灌注室血液致血栓性的研究，以及开发当前SCOR申请中包含的不同项目所需的所有不同血液学和生化参数。临床项目（Dr. V. Fuster）包括约500项灌注研究。糖尿病（n=50）和高脂血症（n=50）患者队列将在基线和治疗开始后3个月、9个月和18个月进行研究;吸烟者将在基线和戒烟后4周进行研究。将在基线、治疗开始后3个月、9个月和18个月监测这些患者的TFPI、TF抗原和活性、C反应蛋白的血浆水平。此外，中心还将负责测定通过我们与逆转录病毒和女性健康研究的研究者合作获得的样本中的TIPI和TF抗原和活性（见Fuster博士的项目）。核心将负责确定和管理临床项目中涉及的高血压、糖尿病和吸烟者的生化数据（D。V. Fuster）。核心还将负责Taubman博士和Nemerson项目中描述的所有血液促凝性研究，以及本项目实验研究中TF抗原和活性、TIPI、C-反应蛋白和肌钙蛋白-I的血浆水平测定。Core还将监测Taubman项目动物的抗凝水平（aPTT、PTT、TT）和血细胞计数（通过使用配备兽医软件的细胞计数器）以及Harpel博士项目动物的胆固醇水平。